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Abstract
Early diagnosis of lung cancer by low-dose computed tomography is an effective strategy to reduce cancer mortality in high-risk individu-
als. However, recruitment of at-risk individuals with asymptomatic lung cancer still remains challenging. We developed a minimal invasive 
serum test, based on the detection of circulating microRNAs, which can identify at-risk individuals with asymptomatic early stage non-
small cell lung carcinomas with 80% accuracy.
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Background and discussions
Lung cancer is the leading cause of cancer-related deaths in the developed world, accounting for 156,940 estimated deaths in 2011 in the 
US alone [1]. The lethality of lung cancer is primarily due to the lack of effective strategies for early detection, at a stage when the tumour 
would still be curable by surgery. However, detection of early stage lung cancer is challenging due to its frequent absence of symptoms [2]. 
This explains the urgent need for early detection screening programs for lung cancer in high-risk individuals, i.e. current or former heavy 
smokers (>20 packs/year) aged 50 years or above.
Low-dose spiral computed tomography (LD-CT) is an effective detection method for small lung nodules (even less than 5 mm) that sub-
jects patients to low radiation exposure with no contrast medium, has limited costs and requires only a few seconds of execution [3,4]. 
The recent report from the large randomised National Lung Screening Trial has demonstrated a mortality reduction of 20% in the arm 
screened by LD-CT compared with the arm screened by chest x-ray [5]. However, recruitment of at-risk individuals with no symptoms of 
disease is still demanding.
In such a scenario, the development of blood tests able to detect the presence of lung cancer might form the cornerstone for successful 
population-based cancer screenings. In recent years there have been many attempts to identify serum/plasma biomarkers for lung cancer 
detection. Some studies have been based on detection through an enzyme-linked immunosorbent assay (ELISA) of circulating tumour-
associated antigens (TAA) such as p53, NY-ESO-1, CAGE, GBU 4-5, annexin, or SOX2, which displayed an overall good specificity and 
sensitivity (40% sensitivity, 90% specificity [6]). Others have relied on the detection of circulating cancer cells in the blood of patients with 
metastatic tumours [7]. Such chip-based tests show sensitivity and specificity in detecting cancer cells that is close to 100% [8], warrant-
ing further investigations into the applicability of the detection circulating cancer cells at earlier stages of disease.
Recently, we and others have identified a subset of circulating microRNAs (miRNAs) accurate enough to detect symptomatic lung cancer 
[9–13] and, more importantly, LD-CT-detected asymptomatic lung cancer [14,15]. The detection of circulating miRNAs may be a valid alter-
native to LD-CT for the early diagnosis of cancer [16], since these tiny molecules are only marginally affected by degradation [17] and can 
be easily quantified by real-time PCR, a method routinely used in the clinic. In a series of experiments described in more detail elsewhere 
[14], we used real-time PCR to identify an expression profile of miRNAs extracted from the sera of participants enrolled in a large single-
centre observational study (COSMOS study [18]). Among the 147 miRNAs detected by real-time PCR, 34 showed differences in expres-
sion in asymptomatic LD-CT-detected lung adenocarcinoma versus normal sera. We developed a multivariate risk-predictor algorithm 
based on the weighted linear combination of the 34-miRNA expression levels. When the predictor was tested on an independent cohort 
of patients with asymptomatic LD-CT-detected lung cancer, it displayed an overall accuracy of 80% (sensitivity 71%, specificity 90%; AUC 
0.89). Furthermore, through a series of additional experiments, we also showed that the risk-predictor was able to distinguish between 
LD-CT-detected benign nodules and frankly malignant disease. This very important finding demonstrates the specificity of the test and 
highlights its utility in the clinic, because of the relative high number of benign lung nodules detected by LD-CT screening [19,20].
The simplicity of the procedure (it is minimally invasive, requiring <1 ml of serum) and its relatively low cost (based on standard real-time 
PCR) should encourage population compliance to large-scale screening programs, thus accelerating its application in the clinic as a ‘first 
line screening test’ to identify those high-risk individuals who should undergo further testing, including by LD-CT (Figure 1). However, 
unresolved questions still remain (as for all newly proposed genomic blood tests) regarding tumour specificity.
We tried to initially address this issue by including in our analysis also a group of patients with invasive ductal breast carcinoma or with 
benign breast fibroadenoma, as a control. The test resulted to be negative in this additional group of patients, thus demonstrating a certain 
specificity of the 34-miRNA test for lung cancer detection [14].
Lastly, a critical issue relates to the origin of serum circulating miRNAs and their biological function. The current model implies that miRNA 
are released in membrane-bound vesicles [21–23], which protect them from blood RNAse activity [24–26]. Such kind of vesicles could be 
either exosomes, 50–90 nm vesicles of endocytic origin arising by inward budding of multivesicular bodies and released by exocytosis [27], 
or microvesicles, larger (up to 1 um) membrane-bound particles generally derived by membrane shedding of several cell types [24,28].
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Strikingly, tumour cells appear to communicate through exosomes with immune cells, leading to immune suppression [29,30]. It is tempt-
ing to speculate that lung cancer cells might reprogram the tumour microenvironment, perhaps by altering the expression patterns of 
surrounding cells, including those of the immune system, through miRNAs contained in exosomes. Undoubtedly, future studies will shed 
more light on the biological functions of circulating miRNAs and their role, if any, in cancer progression. Such studies will allow research-
ers to design completely novel strategies for lung cancer therapy.
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Figure 1: Overview of lung cancer early detection mass population screening.
ecancer 2012, 6:246
www.ecancer.org 4
V
is
io
ns
References
 1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61 69–90 
PMID: 21296855 DOI: 10.3322/caac.20107
 2. Diederich S, Wormanns D (2004) Impact of low-dose CT on lung cancer screening. Lung Cancer 45 Suppl 2 S13–9 
PMID: 15552777 DOI: 10.1016/j.lungcan.2004.07.997
 3. Mulshine JL, Sullivan DC (2005) Clinical practice. Lung cancer screening. N Engl J Med 352 2714–20 PMID: 15987920 
DOI: 10.1056/NEJMcp042630
 4. Humphrey LL, Teutsch S, Johnson M; U.S. Preventive Services Task Force (2004) Lung cancer screening with sputum cytologic 
examination, chest radiography, and computed tomography: an update for the U.S. Preventive Services Task Force. Ann 
Intern Med 140 740–53 PMID: 15126259
 5. Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD; National 
Lung Screening Trial Research Team (2011) Reduced lung-cancer mortality with low-dose computed tomographic screening. 
N Engl J Med 365 395–409 PMID: 21714641 DOI: 10.1056/NEJMoa1102873
 6. Boyle P, Chapman CJ, Holdenrieder S, Murray A, Robertson C, Wood WC, Maddison P, Healey G, Fairley GH, Barnes AC, 
Robertson JF (2011) Clinical validation of an autoantibody test for lung cancer. Ann Oncol 22 383–9 PMID: 20675559 
DOI: 10.1093/annonc/mdq361
 7. Maheswaran S, Sequist LV, Nagrath S, Ulkus L, Brannigan B, Collura CV, Inserra E, Diederichs S, Iafrate AJ, Bell DW, Digumarthy 
S, Muzikansky A, Irimia D, Settleman J, Tompkins RG, Lynch TJ, Toner M, Haber DA (2008) Detection of mutations in EGFR in 
circulating lung-cancer cells. N Engl J Med 359 366–77 PMID: 18596266 DOI: 10.1056/NEJMoa0800668
 8. Nagrath S, Sequist LV, Maheswaran S, Bell DW, Irimia D, Ulkus L, Smith MR, Kwak EL, Digumarthy S, Muzikansky A, Ryan P, Balis 
UJ, Tompkins RG, Haber DA, Toner M (2007) Isolation of rare circulating tumour cells in cancer patients by microchip technol-
ogy. Nature 450 1235–9 PMID: 18097410 DOI: 10.1038/nature06385
 9. Foss KM, Sima C, Ugolini D, Neri M, Allen KE, Weiss GJ (2011) miR-1254 and miR-574-5p: serum-based microRNA biomarkers 
for early-stage non-small cell lung cancer. J Thorac Oncol 6 482–8 PMID: 21258252 DOI: 10.1097/JTO.0b013e318208c785
10. Heegaard NH, Schetter AJ, Welsh JA, Yoneda M, Bowman ED, Harris CC (2012) Circulating micro-RNA expression profiles in 
early stage nonsmall cell lung cancer. Int J Cancer 130 1378–86 PMID: 21544802 DOI: 10.1002/ijc.26153
11. Hu Z, Chen X, Zhao Y, Tian T, Jin G, Shu Y, Chen Y, Xu L, Zen K, Zhang C, Shen H (2010) Serum microRNA signatures identi-
fied in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. J Clin Oncol 28 
1721–6 PMID: 20194856 DOI: 10.1200/JCO.2009.24.9342
12. Shen J, Todd NW, Zhang H, Yu L, Lingxiao X, Mei Y, Guarnera M, Liao J, Chou A, Lu CL, Jiang Z, Fang H, Katz RL, Jiang F 
(2011) Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. Lab Invest 91 579–87 PMID: 21116241 
DOI: 10.1038/labinvest.2010.194
13. Zheng D, Haddadin S, Wang Y, Gu LQ, Perry MC, Freter CE, Wang MX (2011) Plasma microRNAs as novel biomarkers for early 
detection of lung cancer. Int J Clin Exp Pathol 4 575–86 PMID: 21904633
14. Bianchi F, Nicassio F, Marzi M, Belloni E, Dall’olio V, Bernard L, Pelosi G, Maisonneuve P, Veronesi G, Di Fiore PP (2011) A serum 
circulating miRNA diagnostic test to identify asymptomatic high-risk individuals with early stage lung cancer. EMBO Mol 
Med 3 495–503 PMID: 21744498 DOI: 10.1002/emmm.201100154
15. Boeri M, Verri C, Conte D, Roz L, Modena P, Facchinetti F, Calabrò E, Croce CM, Pastorino U, Sozzi G (2011) MicroRNA signatures 
in tissues and plasma predict development and prognosis of computed tomography detected lung cancer. Proc Natl Acad 
Sci USA 108 3713–8 PMID: 21300873 DOI: 10.1073/pnas.1100048108
www.ecancer.org 5
ecancer 2012, 6:246
V
is
io
ns
16. Lin PY, Yang PC (2011) Circulating miRNA signature for early diagnosis of lung cancer. EMBO Mol Med 3 436–7 PMID: 
21739607 DOI: 10.1002/emmm.201100155
17. Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, Guo J, Zhang Y, Chen J, Guo X, Li Q, Li X, Wang W, Zhang Y, Wang J, Jiang X, Xiang Y, 
Xu C, Zheng P, Zhang J, Li R, Zhang H, Shang X, Gong T, Ning G, Wang J, Zen K, Zhang J, Zhang CY (2008) Characterization of 
microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18 997–1006 PMID: 
18766170 DOI: 10.1038/cr.2008.282
18. Veronesi G, Bellomi M, Mulshine JL, Pelosi G, Scanagatta P, Paganelli G, Maisonneuve P, Preda L, Leo F, Bertolotti R, Solli P, 
Spaggiari L (2008) Lung cancer screening with low-dose computed tomography: a non-invasive diagnostic protocol for 
baseline lung nodules. Lung Cancer 61 340–9 PMID: 18308420 DOI: 10.1016/j.lungcan.2008.01.001
19. Bach PB, Jett JR, Pastorino U, Tockman MS, Swensen SJ, Begg CB (2007) Computed tomography screening and lung cancer 
outcomes. JAMA 297 953–61 PMID: 17341709 DOI: 10.1001/jama.297.9.953
20. Swensen SJ, Jett JR, Hartman TE, Midthun DE, Sloan JA, Sykes AM, Aughenbaugh GL, Clemens MA (2003) Lung cancer screen-
ing with CT: Mayo Clinic experience. Radiology 226 756–61 PMID: 12601181 DOI: 10.1148/radiol.2263020036
21. Kosaka N, Iguchi H, Yoshioka Y, Takeshita F, Matsuki Y, Ochiya T (2010) Secretory mechanisms and intercellular transfer of 
microRNAs in living cells. J Biol Chem 285 17442–52 PMID: 20353945 DOI: 10.1074/jbc.M110.107821
22. Skog J, Würdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, Curry WT Jr, Carter BS, Krichevsky AM, Breakefield 
XO (2008) Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic 
biomarkers. Nat Cell Biol 10 1470–6 PMID: 19011622 DOI: 10.1038/ncb1800
23. Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO (2007) Exosome-mediated transfer of mRNAs and microRNAs 
is a novel mechanism of genetic exchange between cells. Nat Cell Biol 9 654–9 PMID: 17486113 DOI: 10.1038/ncb1596
24. Hunter MP, Ismail N, Zhang X, Aguda BD, Lee EJ, Yu L, Xiao T, Schafer J, Lee ML, Schmittgen TD, Nana-Sinkam SP, Jarjoura 
D, Marsh CB (2008) Detection of microRNA expression in human peripheral blood microvesicles. PLoS ONE 3 e3694 
PMID: 19002258 DOI: 10.1371/journal.pone.0003694
25. Taylor DD, Gercel-Taylor C (2008) MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian 
cancer. Gynecol Oncol 110 13–21 PMID: 18589210 DOI: 10.1016/j.ygyno.2008.04.033
26. Rabinowits G, Gerçel-Taylor C, Day JM, Taylor DD, Kloecker GH (2009) Exosomal microRNA: a diagnostic marker for lung can-
cer. Clin Lung Cancer 10 42–6 PMID: 19289371 DOI: 10.3816/CLC.2009.n.006
27. Février B, Raposo G (2004) Exosomes: endosomal-derived vesicles shipping extracellular messages. Curr Opin Cell Biol 16 
415–21 PMID: 15261674 DOI: 10.1016/j.ceb.2004.06.003
28. Heijnen HF, Schiel AE, Fijnheer R, Geuze HJ, Sixma JJ (1999) Activated platelets release two types of membrane vesicles: 
microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha-granules. 
Blood 94 3791–9 PMID: 10572093
29. Yu S, Liu C, Su K, Wang J, Liu Y, Zhang L, Li C, Cong Y, Kimberly R, Grizzle WE, Falkson C, Zhang HG (2007) Tumor exosomes 
inhibit differentiation of bone marrow dendritic cells. J Immunol 178 6867–75 PMID: 17513735
30. Chalmin F, Ladoire S, Mignot G, Vincent J, Bruchard M, Remy-Martin JP, Boireau W, Rouleau A, Simon B, Lanneau D, De Thonel 
A, Multhoff G, Hamman A, Martin F, Chauffert B, Solary E, Zitvogel L, Garrido C, Ryffel B, Borg C, Apetoh L, Rébé C, Ghiringhelli F 
(2010) Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppressive func-
tion of mouse and human myeloid-derived suppressor cells. J Clin Invest 120 457–71 PMID: 20093776 DOI: 10.1172/JCI40483
